论文部分内容阅读
目的 探讨 p5 3、c erbB 2、PCNA蛋白的表达与大肠癌的临床病理意义以及其对大肠癌预后判断的价值。方法 应用免疫组化技术对 5 3例大肠癌进行上述指标的表达及对比研究。结果 大肠癌p5 3、PCNA、c erbB 2阳性表达分别为 5 2 .83%、96 .2 3%、5 4 .72 %。p5 3、PCNA、c erbB 2共同阳性表达率为 37.74 % ,与大肠癌患者年龄、性别、发病部位、纤维的增生程度、淋巴细胞的浸润及组织学类型无关 (P >0 .0 5 ) ,与癌组织的浸润深度、淋巴结转移有关 (P <0 .0 5 )。纤维组织的增生程度与癌组织浸润程度呈负相关 (r1=- 0 .4 2 13,P <0 .0 5 )有参考价值。结论 p5 3、c erbB 2、PCNA的联合检测对判断大肠癌预后有参考价值。
Objective To investigate the clinicopathological significance of p5 3, c erbB 2 and PCNA in colorectal cancer and their prognostic value in colorectal cancer. Methods Fifty cases of colorectal carcinoma were immunohistochemically expressed and compared with the above indexes. Results The positive expressions of p5 3, PCNA and c erbB 2 in colorectal cancer were 52.33%, 96.23% and 54.72% respectively. The positive expression rate of PCNA and c erbB 2 was 37.74%, which was not associated with the age, sex, location of disease, the degree of fibrosis, infiltration of lymphocytes and histological types in patients with colorectal cancer (P> 0.05) With the depth of invasion and lymph node metastasis (P <0.05). The degree of hyperplasia of fibrous tissue was negatively correlated with the degree of infiltration of cancer (r1 = - 0.4213, P <0.05). Conclusion The combined detection of p5 3, c erbB 2 and PCNA has a reference value for judging the prognosis of colorectal cancer.